-
Ferring Pharmaceuticals appoints Alex Chang Senior Vice President, Asia Pacific
-Ferring Pharmaceuticals announced today that it has appointed Alex Chang to head the company’s Asia Pacific region effective 1 November 2013…
-
MISODEL™, Ferring’s removable misoprostol vaginal delivery system, approved for labour induction in European Decentralised Procedure
-Ferring Pharmaceuticals announced today that its MISODELTM (misoprostol) removable, controlled-release vaginal delivery system for labour induction…
-
Ferring announces second $3 million donation to the Royal Textile Academy of Bhutan
-Ferring Pharmaceuticals has announced a second $3 million donation to the Royal Textile Academy of Bhutan to support its mission to preserve and…
-
Ferring presents phase III data for a controlled release misoprostol vaginal delivery system for labour induction at the First European Congress on Intrapartum Care
-Data from the EXPEDITE study presented today at the First European Congress on Intrapartum Care (ECIC) demonstrated…
-
Ferring Pharmaceuticals begins phase III trials of elobixibat, new compound with novel mechanism of action for chronic idiopathic constipation
-Ferring Pharmaceuticals today announced it has initiated enrolment of patients in two phase III clinical trials…
-
Ferring to Present Safety Analysis for FIRMAGON® (degarelix) at the American Urological Association Annual Meeting
-The following data will be presented at the annual meeting of the American Urological Association (AUA) in San Diego…
-
New data highlight considerable burden of Nocturia
-New data presented today at the European Association of Urology (EAU) congress show that nocturia (waking up one or more times to void at night)…
-
Data suggest lower risk of cardiovascular events or deaths in prostate cancer patients treated with degarelix compared to LHRH agonists
-Data presented today at the European Association of Urology (EAU) 2013 annual meeting in Milan, indicate that the gonadotropin releasing hormone…
-
In patients with active, left-sided ulcerative colitis, study shows once-daily dose of mesalazine granules provided similar results to twice-daily dose
-Results of a recent sub analysis1 of data from the MOTUS study2 presented today at the Congress of European Crohn’s and Colitis Organisation…
PRESS RELEASE 2013
PRESS RELEASE 2013